中生制药(01177.HK)第二代氟比洛芬贴剂获批上市

阿斯达克财经
Aug 06

中生制药(01177.HK) 公布,附属北京泰德的国家5.1类新药第二代氟比洛芬贴剂,商品名为泽普思,已获得国家药品监督管理局(NMPA)批准上市,用于镇痛、消炎:骨关节炎、肩周炎、肌腱及腱鞘炎、腱鞘周围炎、肱骨外上髁炎(网球肘)、肌肉痛、外伤所致肿胀、疼痛。该产品亦获得NMPA 4年数据保护期。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-06 16:25。)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10